Dopamine Agonists Face Growing Liability Over Gambling and Other Impulse-Control Disorders

Courts in Europe, North America and Australia have increasingly held manufacturers of dopamine-agonist drugs liable for impulse-control disorders such as pathological gambling, compulsive shopping, binge eating and hypersexuality. In France, an appeals court in Rennes raised a government official’s award to €197,000 after finding the drug’s risk was never effectively warned. In the United States, a Minnesota jury in 2008 awarded $8.3 million—$7.8 million in punitive damages—to a pramipexole patient for delayed labeling. Australian federal courts approved confidential multimillion-dollar settlements for hundreds of patients who lost money on poker machines after taking cabergoline (2015) and for a smaller group exposed to pergolide (2013). Italy’s Milan court of appeals in 2021 upheld a €484,000 judgment against a pergolide maker while dismissing ropinirole suits for lack of individual causation. A 2026 European Court of Justice ruling (Case C-440/23) affirmed that consumers may recover lost stakes from foreign casino operators, expanding recovery avenues.

Dopamine Agonists, Gambling, and Drug-Maker Liability

Dopamine agonists—including ropinirole, pramipexole, cabergoline and pergolide—are prescribed for Parkinson’s disease and restless-legs syndrome. The DOMINION trial (2010) screened 3,090 Parkinson’s patients and found impulse-control disorders (ICDs) in 13.6 % overall; among those on dopamine agonists the prevalence rose to roughly 17 %, with pathological gambling affecting 5 %. Risk escalates with dose and typically subsides when the drug is reduced or stopped. Because the disorder impairs patients’ ability to recognize the behavior as a symptom, warnings that rely on self-assessment have limited protective value.

Dopamine Agonists, Gambling, and Drug-Maker Liability

• 2000 – First reports linking dopamine agonists to gambling.

Dopamine Agonists, Gambling, and Drug-Maker Liability

• 2005 – U.S. label for pramipexole updated to mention compulsive behaviors.

Dopamine Agonists, Gambling, and Drug-Maker Liability

• 2008 – Minnesota jury awards $8.3 million to Gary Charbonneau for delayed warning.

Dopamine Agonists, Gambling, and Drug-Maker Liability

• 2010 – DOMINION study quantifies ICD prevalence.

Dopamine Agonists, Gambling, and Drug-Maker Liability

• 2012 – Rennes appeals court raises French award to €197,000.

Dopamine Agonists, Gambling, and Drug-Maker Liability

• 2015 – Australian court approves settlement for 172 cabergoline patients.

Dopamine Agonists, Gambling, and Drug-Maker Liability

• 2021 – Milan court upholds €484,000 award for pergolide-induced gambling; ropinirole suits dismissed.

Dopamine Agonists, Gambling, and Drug-Maker Liability

• 2024 – EU adopts a product-liability directive easing access to manufacturers’ internal files.

Dopamine Agonists, Gambling, and Drug-Maker Liability

• April 16 2026 – ECJ (Case C-440/23) confirms consumers may claim restitution from foreign casino operators.

Dopamine Agonists, Gambling, and Drug-Maker Liability

• Incidence: About one in six patients on a dopamine agonist develops a compulsive behavior; one in twenty experiences pathological gambling.

Dopamine Agonists, Gambling, and Drug-Maker Liability

• Risk Magnitude: Treatment raises odds of an ICD by 2–3.5 times compared with non-agonist therapy.

Dopamine Agonists, Gambling, and Drug-Maker Liability

• Financial Harm: Reported individual losses include $260,000 (Charbonneau) and €484,000 (Italian case).

Dopamine Agonists, Gambling, and Drug-Maker Liability

• Settlement Scale: Australian cabergoline settlement covered 172 patients; a separate pergolide settlement involved 32 patients.

Dopamine Agonists, Gambling, and Drug-Maker Liability

Manufacturers argue that regulators never mandated label changes and that some plaintiffs gambled before drug exposure. Courts have rejected these defenses when evidence showed a clear temporal link between dose escalation and compulsive behavior, and when warnings were deemed ineffective. Polish law now requires product safety to be judged partly by the information supplied to consumers, and the upcoming EU directive will further lower evidentiary barriers in scientifically complex cases.

Dopamine Agonists, Gambling, and Drug-Maker Liability

The EU product-liability directive slated for 2024 will, once transposed, grant claimants broader access to manufacturers’ internal data and simplify the burden of proof. Polish courts have yet to issue a landmark judgment on dopamine-agonist-induced ICDs, suggesting that the first well-documented cases will shape future jurisprudence. Patients and clinicians are advised to document behavioral changes contemporaneously, preserve medical and financial records, and report adverse reactions promptly to national drug agencies to support both safety monitoring and potential legal claims.

Dopamine Agonists, Gambling, and Drug-Maker Liability